Patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect our intellectual property rights.
Products: Maxygen seeks patent protection for its product candidates in the U.S. and other selected jurisdictions.
MAXY G34 (G-CSF)
MAXY-alpha (interferon alpha)
MAXY-gamma (interferon gamma)
Recombination-Based Directed Evolution Technologies. Maxygen has what we believe to be the most comprehensive patent portfolio in recombination-based directed evolution technologies for the creation of new and improved protein products, as well as patents for complementary protein modification technologies.
Patents owned by us, or for which we have exclusive licenses, cover a broad range of activities surrounding recombination-based directed molecular evolution including:
- methods for template-based gene recombination to produce chimeric genes;
- methods for recombining nucleic acid segments produced by incomplete nucleic acid chain extension reactions to produce chimeric genes including the staggered extension process (StEP);
- methods utilizing reiterative screening or only a single cycle of screening;
- methods of combining any mutagenesis technique with DNA recombination methods to produce new chimeric genes;
- methods using synthesized nucleic acid fragments; and
- in vivo and in vitro recombination methods of the above, in a variety of formats.
Such patents reinforce our position as an industry leader in the use of recombination-based directed molecular evolution for commercial applications.
We also have exclusively licensed patent rights and technology relating to our recombination-based directed evolution technologies for specific uses from the California Institute of Technology (Caltech) and the University of Washington.
Issued U.S. Patents owned by Maxygen relating to our recombination-based directed evolution technologies.
Return to Science & Technology
|
